ABSTRACT
The dopaminergic (DA) systems have been the focus of much research over the past three decades, mainly because several neurological diseases such as Parkinson’s disease, Huntington disease, and Tourette’s syndrome have been linked to malfunctioning of dopaminergic transmission. Furthermore, dopamine receptor agonists such as Ropinirole, pramipexole, and cabergoline have been used to treat Parkinson’s disease, and dopamine receptor antagonists such as chlorpromazine, haloperidol, and risperidone have been used to treat schizophrenia.
